This article attempts to provide a clear view of Teva's financials.
This article aims to look at this investment with sufficient margin of safety.
Copaxone stressed by 50% profit segment decline.
This is to assist a very heated discussion in the prior post, "Teva: Walking Dead?”
I am not assuming that Teva (NYSE:TEVA) continues acquiring further companies in the years to come. Assuming this